DE69232351T2 - Ribozymstruktur die von den genomischen rns des hepatitis delta virus abgeleitet ist - Google Patents
Ribozymstruktur die von den genomischen rns des hepatitis delta virus abgeleitet istInfo
- Publication number
- DE69232351T2 DE69232351T2 DE69232351T DE69232351T DE69232351T2 DE 69232351 T2 DE69232351 T2 DE 69232351T2 DE 69232351 T DE69232351 T DE 69232351T DE 69232351 T DE69232351 T DE 69232351T DE 69232351 T2 DE69232351 T2 DE 69232351T2
- Authority
- DE
- Germany
- Prior art keywords
- nucleotides
- ribozyme
- ribozyme structure
- structure according
- fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 241000724709 Hepatitis delta virus Species 0.000 title claims description 15
- 239000012634 fragment Substances 0.000 claims abstract description 35
- 230000000694 effects Effects 0.000 claims abstract description 25
- 230000003197 catalytic effect Effects 0.000 claims abstract description 22
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 11
- 150000007523 nucleic acids Chemical group 0.000 claims abstract description 10
- 102000053642 Catalytic RNA Human genes 0.000 claims description 71
- 108090000994 Catalytic RNA Proteins 0.000 claims description 71
- 108091092562 ribozyme Proteins 0.000 claims description 71
- 239000002773 nucleotide Substances 0.000 claims description 48
- 125000003729 nucleotide group Chemical group 0.000 claims description 40
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 31
- 239000000758 substrate Substances 0.000 claims description 17
- 241001465754 Metazoa Species 0.000 claims description 6
- 230000000069 prophylactic effect Effects 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 238000003776 cleavage reaction Methods 0.000 abstract description 10
- 241000700605 Viruses Species 0.000 abstract description 8
- 230000007017 scission Effects 0.000 abstract description 8
- 210000003705 ribosome Anatomy 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 description 8
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 229920002401 polyacrylamide Polymers 0.000 description 5
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- 102000006382 Ribonucleases Human genes 0.000 description 3
- 108010083644 Ribonucleases Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 210000004102 animal cell Anatomy 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 description 3
- 239000012429 reaction media Substances 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 2
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 2
- 101710137500 T7 RNA polymerase Proteins 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 238000000376 autoradiography Methods 0.000 description 2
- 241001493065 dsRNA viruses Species 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 108091028732 Concatemer Proteins 0.000 description 1
- 102100030011 Endoribonuclease Human genes 0.000 description 1
- 108010093099 Endoribonucleases Proteins 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 102000004167 Ribonuclease P Human genes 0.000 description 1
- 108090000621 Ribonuclease P Proteins 0.000 description 1
- 108020004487 Satellite DNA Proteins 0.000 description 1
- 241000251131 Sphyrna Species 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 229940063673 spermidine Drugs 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 230000017613 viral reproduction Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/123—Hepatitis delta
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3517—Marker; Tag
Landscapes
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9110872A FR2680797A1 (fr) | 1991-09-03 | 1991-09-03 | Structure ribozymique derivee de l'arn genomique du virus de l'hepatite delta. |
| PCT/FR1992/000840 WO1993005157A1 (fr) | 1991-09-03 | 1992-09-03 | Structure ribozymique derivee de l'arn genomique du virus de l'hepatite delta |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69232351D1 DE69232351D1 (de) | 2002-02-21 |
| DE69232351T2 true DE69232351T2 (de) | 2002-09-26 |
Family
ID=9416576
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69232351T Expired - Fee Related DE69232351T2 (de) | 1991-09-03 | 1992-09-03 | Ribozymstruktur die von den genomischen rns des hepatitis delta virus abgeleitet ist |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP0602157B1 (enExample) |
| JP (1) | JPH06510196A (enExample) |
| AT (1) | ATE212057T1 (enExample) |
| AU (1) | AU669487B2 (enExample) |
| DE (1) | DE69232351T2 (enExample) |
| FR (1) | FR2680797A1 (enExample) |
| WO (1) | WO1993005157A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU683011B2 (en) * | 1992-01-13 | 1997-10-30 | Duke University | Enzymatic RNA molecules |
| CA2230203A1 (en) | 1998-04-29 | 1999-10-29 | Universite De Sherbrooke | Delta ribozyme for rna cleavage |
| CN107287352A (zh) * | 2017-08-02 | 2017-10-24 | 山东省农业科学院家禽研究所 | 鸭肠炎病毒和鸭肝炎病毒快速检测的探针引物组及其方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225337A (en) * | 1989-09-25 | 1993-07-06 | Innovir Laboratories, Inc. | Ribozyme compositions and methods for use |
| US5225347A (en) * | 1989-09-25 | 1993-07-06 | Innovir Laboratories, Inc. | Therapeutic ribozyme compositions and expression vectors |
-
1991
- 1991-09-03 FR FR9110872A patent/FR2680797A1/fr active Granted
-
1992
- 1992-09-03 DE DE69232351T patent/DE69232351T2/de not_active Expired - Fee Related
- 1992-09-03 AT AT92919440T patent/ATE212057T1/de not_active IP Right Cessation
- 1992-09-03 JP JP5505002A patent/JPH06510196A/ja active Pending
- 1992-09-03 WO PCT/FR1992/000840 patent/WO1993005157A1/fr not_active Ceased
- 1992-09-03 AU AU25583/92A patent/AU669487B2/en not_active Ceased
- 1992-09-03 EP EP92919440A patent/EP0602157B1/fr not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP0602157B1 (fr) | 2002-01-16 |
| EP0602157A1 (fr) | 1994-06-22 |
| AU669487B2 (en) | 1996-06-13 |
| JPH06510196A (ja) | 1994-11-17 |
| WO1993005157A1 (fr) | 1993-03-18 |
| ATE212057T1 (de) | 2002-02-15 |
| AU2558392A (en) | 1993-04-05 |
| DE69232351D1 (de) | 2002-02-21 |
| FR2680797A1 (fr) | 1993-03-05 |
| FR2680797B1 (enExample) | 1995-01-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE68927456T2 (de) | RNS-Katalysator zur Spaltung von spezifischen RNS-Sequenzen | |
| DE60034396T2 (de) | Reaktionsgemisch und Verfahren für RT-PCR mittels einer homopolymeren Nukleinsäure | |
| DE3852539T3 (de) | Ribozyme. | |
| DE69725861T2 (de) | Katalytische nukleinsäuren und deren medizinische verwendung | |
| DE69232457T2 (de) | Verwendung einer exo-nukleotidprobe in der genklonierung | |
| DE69604775T2 (de) | Genexpressionuntersuchung durch aufzeigen von cdna 3'-restriktionsfragmenten | |
| DE69827745T2 (de) | Kovalente bindung von dna zu rna strängen katalysiert durch vaccinia topoisomerase | |
| DE68926484T2 (de) | RNS-Template mit endverbundener Sonde und Verfahren zur Verwendung | |
| DE69216385T2 (de) | Gekoppelte transkription und translation in zellfreien eukaryoten-extrakten | |
| DE69232032T3 (de) | Antisense oligonukleotide | |
| DE69734913T2 (de) | Verfahren für reverse Transkription | |
| EP0718408B1 (de) | Verfahren zum besonders sensitiven Nachweis von Nukleinsäuren | |
| DE69125374D1 (en) | Endonukleasen | |
| DE19812103A1 (de) | Verfahren zur Synthese von Nucleinsäuremolekülen | |
| ATE27185T1 (de) | Verfahren zum herstellen einer metallischen fluessig-fest-mischung. | |
| DE2315501A1 (de) | Verfahren zur bestimmung von cholesterin | |
| DE10119005A1 (de) | Verfahren zur Proteinexpression ausgehend von stabilisierter linearer kurzer DNA in zellfreien in vitro-Transkription/Translations-Systemen mit Exonuklease-haltigen Lysaten oder in einem zellulären System enthaltend Exonukleasen | |
| DE69613336T2 (de) | Chimere ribozym-snRNA Moleküle mit katalytischen Aktivität nuklearer RNAs | |
| Lenox et al. | Site-specific generation of deoxyribonolactone lesions in DNA oligonucleotides | |
| EP0776363A1 (de) | Ribozym-bibliothek, ihre herstellung und ihre verwendung | |
| EP1556486B1 (de) | Wirksame und stabile dna-enzyme | |
| DE69114844T2 (de) | Enzymatisches amplifizierungsverfahren in vitro. | |
| DE60131101T2 (de) | pRNA-CHIMÄRE | |
| DE4332463A1 (de) | Verfahren zur spezifischen Klonierung von Nukleinsäuren | |
| EP0299303B1 (de) | Eukaryotische Expressionsvektoren mit multimeren Enhancer-Subelementen, Verfahren zu ihrer Herstellung und Verwendung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |